Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Artivion, Inc. Common Stock (NY:AORT)

43.37 +1.07 (+2.53%)
Streaming Delayed Price Updated: 3:56 PM EDT, Oct 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Artivion, Inc. Common Stock

< Previous 1 2 3 4 Next >
Firing on All Cylinders: Artivion (NYSE:AORT) Q2 Earnings Lead the Way
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the medical devices & supplies - cardiology, neurology, vascular stocks, including Artivion (NYSE:AORT) and its peers. 
Via StockStory
3 Reasons to Sell AORT and 1 Stock to Buy Instead
What a fantastic six months it’s been for Artivion. Shares of the company have skyrocketed 78.2%, hitting $41.02. This was partly thanks to its solid quarterly results, and the performance may have... 
Via StockStory
Topics Supply Chain
1 High-Flying Stock on Our Buy List and 2 We Find Risky
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lofty expectations make them particularly... 
Via StockStory
Beyond The Numbers: 7 Analysts Discuss Artivion Stock
Across the recent three months, 7 analysts have shared their insights on Artivion (NYSE: AORT), expressing a variety of opinions spanning from bullish to bearish. 
Via Benzinga
Earnings Scheduled For August 7, 2025
 
Via Benzinga
3 Russell 2000 Stocks with Warning Signs
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the... 
Via StockStory
Select Medical, Guardant Health, Artivion, PacBio, and Intuitive Surgical Shares Are Falling, What You Need To Know
A number of stocks fell in the afternoon session after markets pulled back, reversing early gains, as investor sentiment remained cautious despite a softer-than-expected inflation reading. 
Via StockStory
Topics Economy Stocks
3 Stocks Under $50 We’re Skeptical Of
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to... 
Via StockStory
Topics Supply Chain
1 Safe-and-Steady Stock to Consider Right Now and 2 We Ignore
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. 
Via StockStory
PNC Financial Services Group, Truist Financial, U.S. Bancorp, Sweetgreen, and Artivion Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices rebounded, as Fed Chair Jerome Powell delivered dovish remarks at the much-awaited Jackson Hole symposium. Powell suggested... 
Via StockStory
Topics Economy World Trade
3 Hyped Up Stocks with Questionable Fundamentals
Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage... 
Via StockStory
Topics Supply Chain
1 High-Flying Stock with Exciting Potential and 2 We Find Risky
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lofty expectations make them particularly... 
Via StockStory
1 Safe-and-Steady Stock to Target This Week and 2 We Find Risky
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. 
Via StockStory
AORT Q2 Deep Dive: Product Momentum and Pipeline Advances Drive Upgraded Guidance
Medical device company Artivion (NYSE:AORT) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 15.3% year on year to $113 million. The company’s full-year revenue guidance of $439... 
Via StockStory
Deep Dive Into Artivion Stock: Analyst Perspectives (4 Ratings)
 
Via Benzinga
Why Is Artivion (AORT) Stock Rocketing Higher Today
Shares of medical device company Artivion (NYSE:AORT) jumped 20.3% in the morning session after it reported strong second-quarter 2025 earnings that surpassed analyst expectations and raised its... 
Via StockStory
Artivion (NYSE:AORT) Reports Strong Q2, Stock Jumps 13.1%
Medical device company Artivion (NYSE:AORT) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 15.3% year on year to $113 million. The company’s full-year revenue... 
Via StockStory
Artivion (AORT) Q2 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Artivion (AORT) Q2 EPS Jumps 243%
Via The Motley Fool
Topics Economy
Artivion (AORT) Stock Is Up, What You Need To Know
Shares of medical device company Artivion (NYSE:AORT) jumped 3% in the morning session after investment firm Stifel raised its price target on the stock to $36 from $30, while maintaining a Buy rating.... 
Via StockStory
Topics ETFs Stocks World Trade
What To Expect From Artivion’s (AORT) Q2 Earnings
Medical device company Artivion (NYSE:AORT) will be announcing earnings results this Thursday afternoon. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence Economy World Trade
1 Russell 2000 Stock for Long-Term Investors and 2 We Question
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the... 
Via StockStory
3 Healthcare Stocks with Warning Signs
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six... 
Via StockStory
Topics Stocks
3 Profitable Stocks with Warning Signs
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow. 
Via StockStory
Tandem Diabetes, Solventum, LeMaitre, UFP Technologies, and Artivion Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. The wider market sentiment turned... 
Via StockStory
Topics ETFs Stocks World Trade
3 Small-Cap Stocks Skating on Thin Ice
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a... 
Via StockStory
This Coinbase Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
 
Via Benzinga
Q1 Earnings Highs And Lows: Artivion (NYSE:AORT) Vs The Rest Of The Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the medical devices & supplies - cardiology, neurology, vascular industry, including... 
Via StockStory
AORT Q1 Earnings Call: Early Product Launches and Supply Recovery Drive Outperformance
Medical device company Artivion (NYSE:AORT) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 1.6% year on year to $98.98 million. The company’s full-year revenue... 
Via StockStory
Topics Economy
3 High-Flying Stocks with Questionable Fundamentals
"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated... 
Via StockStory
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.